Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC)

  • STATUS
    Recruiting
  • End date
    Oct 1, 2024
  • participants needed
    20
  • sponsor
    University of Alabama at Birmingham
Updated on 3 May 2022
platelet count
cancer
measurable disease
serum bilirubin
neutrophil count
gemcitabine

Summary

This pilot trial will be used to assess the activity, safety and feasibility of doublet immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma with high risk features. The hypothesis is that the combination of durvalumab/MEDI4736 and tremelimumab (doublet immunotherapy) with platinum-based chemotherapy (gemcitabine and cisplatin) will yield an objective of 52% and improve complete resection rates in intrahepatic cholangiocarcinoma. This will facilitate margin negative resection and ultimately reduce recurrence rates and improve survival. Carrying out this trial in the neoadjuvant setting potentially allows improved overall survival and also provides an opportunity for discovery of biomarkers that may predict response to therapy.

Description

All enrolled participants will receive the study intervention. Patients will receive up to 4 cycles of interventional agents prior to surgical resection. They will undergo imaging scans after the 2nd and 4th cycle (before surgery) of intervention agents. The short interval of scans (6 weeks) allows investigators to identify non responders. These patients may be encouraged to come off study and be treated based on the treating oncologist's choice. Since the investigational agents include 'standard of care' agents, a good argument can be made that these patients would not have benefitted from standard therapy only. Patients with at least stable disease after the 2nd treatment cycle will proceed with study interventions. However, patients with radiologic progression but who remain clinically stable may be allowed to continue treatment if the patient elects to, pending confirmation of progression and after a discussion between the investigator and sponsor-investigator.

Details
Condition Cholangiocarcinoma
Treatment Novel combination of chemotherapy and immunotherapy
Clinical Study IdentifierNCT04989218
SponsorUniversity of Alabama at Birmingham
Last Modified on3 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject must meet all of the following applicable inclusion criteria to participate in this
study
Histologically/cytologically confirmed diagnosed intrahepatic cholangiocarcinoma
Measurable disease based on RECIST 1.1 and have 1 or more radiologic features
compatible with high risk (for resection and recurrence) but still considered
technically resectable per multidisciplinary tumor board (Surgical oncologist
radiologist and medical oncologist minimum) meeting. High risk features would include
at least 1 of the following criteria-
• A large tumor (> 5cm) that would benefit from preoperative tumor shrinkage with
systemic therapy
T1b-T4 tumor thought to be technically resectable
Multifocal tumors/ a tumor with satellite lesions confined to the same lobe
thought to be technically resectable
Suspicious or involved lymph nodes (N1) thought to be technically resectable
Tumor with any vascular involvement/invasion considered technically resectable
No extrahepatic metastases
Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF) and in this
protocol. Written informed consent and any locally required authorization (e.g
Health Insurance Portability and Accountability Act in the US) obtained from the
patient/legal representative prior to performing any protocol-related procedures
including screening evaluations
Adult male or female age >18 years at time of study entry
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of > 6 months
Body weight >30 kg
Adequate normal organ and marrow function as defined below
Hemoglobin ≥ 10.0 g/dL
Absolute neutrophil count (ANC ≥1.5 x 109/L (> 1500 per mm3)
Platelet count ≥100 x 109/L (>75,000 per mm3)
Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not
apply to patients with confirmed Gilbert's syndrome (persistent or recurrent
hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis
or hepatic pathology), who will be allowed only in consultation with the sponsor
AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal Measured
creatinine clearance (CL) >60 mL/min or Calculated creatinine clearance CL>60
mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour
urine collection for determination of creatinine clearance
Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients. Women will be considered post-menopausal if they have
been amenorrhoeic for 12 months without an alternative medical cause. The following
age-specific requirements apply
Women <50 years of age would be considered post-menopausal if they have been
amenorrhoeic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle-stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy)
Women ≥50 years of age would be considered post-menopausal if they have been
amenorrhoeic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced menopause with last menses >1 year ago, had
chemotherapy-induced menopause with last menses >1 year ago, or underwent
surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
hysterectomy)
Patient is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
up
Provide archival tumour tissue sample or newly obtained core or excisional biopsy of a
previously unirradiated tumour lesion. Tissue blocks are preferred but unstained cut
slides acceptable. In addition, should be open to undergoing a biopsy after at least 2
cycles of therapy. Patients who do not undergo surgical resection after 4 cycles will
be advised to undergo another biopsy

Exclusion Criteria

Has had previous local (surgery, radiation, embolizing procedure) or systemic therapy
for borderline resectable intrahepatic cholangiocarcinoma
Participation in another clinical study with an investigational product during the
last 3 months
Concurrent enrolment in another clinical study, unless it is an observational
(non-interventional) clinical study or during the follow-up period of an
interventional study
Has ampullary cancer, extrahepatic cholangiocarcinoma or gall bladder cancer
Patients with distant extrahepatic metastatic disease including distant (non-regional
lymph nodes). NOTE: Regional lymph nodes depend on tumor site; for left sided lesions
regional lymph nodes include inferior phrenic, hilar and gastrohepatic lymph nodes
For right sided lesions, regional lymph nodes include hilar periduodenal and
peripancreatic lymph nodes
Has any other histologic subtype except adenocarcinoma or mixed histology with
adenocarcinoma/hepatocellular carcinoma
Any unresolved toxicity NCI CTCAE Grade > 2 from previous anticancer therapy except
for alopecia, vitiligo and the laboratory values defined in the inclusion criteria
Patients with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after
consultation with the sponsor-investigator
Patients with irreversible toxicity not reasonably expected to be exacerbated by
treatment with durvalumab or tremelimumab may be included only after consultation with
the sponsor-investigator. Any medical contraindication to the use of platinum-based
doublet chemotherapy as judged by the treating physician
Major surgical procedure (as defined by the Investigator) within 28 days prior to
the first dose of study drugs
History of allogenic organ transplantation
Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome
or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this
criterion
• Patients with vitiligo or alopecia
• Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone
replacement
Any chronic skin condition that does not require systemic therapy
Patients without active disease in the last 5 years may be included but only
after consultation with the study physician
Patients with celiac disease controlled by diet alone
Uncontrolled intercurrent illness, including but not limited to, ongoing or active
infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social
situations that would limit compliance with study requirement, substantially increase
risk of incurring AEs or compromise the ability of the patient to give written
informed consent
History of active primary immunodeficiency
History of another primary malignancy except for
• Malignancy treated with curative intent and with no known active disease ≥3 years
before the first dose of IP and of low potential risk for recurrence
• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of
disease
• Adequately treated carcinoma in situ without evidence of disease
Active infection including tuberculosis (clinical evaluation that includes clinical
history, physical examination and radiographic findings, and TB testing in line with
local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result)
Patients with a past or resolved HBV infection (defined as the presence of hepatitis B
core antibody [anti-HBc] and absence of HBsAg) are eligible. hepatitis C, Patients
positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction
is negative for HCV RNA. Testing for HIV is not required at screening but patients
with known HIV disease will be excluded from the study
Current or prior use of immunosuppressive medication within 14 days before the first
dose of durvalumab or tremelimumab. The following are exceptions to this criterion
• Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
articular injection)
Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
prednisone or its equivalent
Steroids as premedication for hypersensitivity reactions (e.g., CT scan
premedication)
Receipt of live attenuated vaccine within 30 days prior to the first dose of study
drug. NOTE: Patients, if enrolled, should not receive live vaccine whilst receiving
study drug and up to 30 days after the last dose of study drug
Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab monotherapy or180 days after
the last dose of durvalumab + tremelimumab combination therapy
Known allergy or hypersensitivity to any of the study drugs or any of the study drug
excipients
Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical
study regardless of treatment arm assignment
Has had severe hypersensitivity (≥ Grade 3) to anti -PD1/PDL1 or anti-CTLA4 therapy
and/or any of their excipients in the past
Patients who have received prior anti-PD-1, anti-PD-L1 or anti-CTLA-4
• Must not have experienced a toxicity that led to permanent discontinuation of prior
immunotherapy. All AEs while receiving prior immunotherapy must have completely
resolved or resolved to baseline prior to screening for this study
Must not have experienced a ≥Grade 3 immune related AE or an immune related
neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE
Patients with endocrine AE of ≤Grade 2 are permitted to enrol if they are stably
maintained on appropriate replacement therapy and are asymptomatic
Must not have required the use of additional immunosuppression other than
corticosteroids for the management of an AE, not have experienced recurrence of
an AE if re-challenged, and not currently require maintenance doses of > 10 mg
prednisone or equivalent per day
Judgment by the investigator that the patient is unsuitable to participate in the
study and the patient is unlikely to comply with study procedures, restrictions and
requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note